摘要

OBJECTIVE %26lt;br%26gt;To design a new experimental model combining erectile dysfunction, prostate enlargement and urodynamic impairment characteristic of lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH). %26lt;br%26gt;MATERIALS AND METHODS %26lt;br%26gt;Three groups of animals (12-week-old; n = 7/group) were considered: Wistar Kyoto (control) rats (WKY), untreated spontaneously hypertensive rats (SHR) and SHR treated with testosterone (SHR-T, 3 mg/kg/day) for 3 weeks. %26lt;br%26gt;Cystometry experiments and evaluation of erectile function were performed. Prostate enlargement was evaluated. %26lt;br%26gt;RESULTS %26lt;br%26gt;SHR displayed a significant decrease in the intercontraction interval (ICI) and in the voided volume (VV) whereas non-voiding contractions (NVC) were increased. SHR-T exhibited a further decreased ICI and VV and an increased frequency of NVC. %26lt;br%26gt;Erectile responses to electrical stimulation of the cavernous nerve were significantly impaired in both SHR (-66%) and SHR-T (-58%). %26lt;br%26gt;The prostate weight was similar in WKY and SHR, but significantly increased in SHR-T. %26lt;br%26gt;CONCLUSIONS %26lt;br%26gt;The testosterone-supplemented SHR represents an experimental model for urodynamic impairment combining both static and dynamic components of voiding symptoms with erectile dysfunction and prostate enlargement. %26lt;br%26gt;This model is suitable for the assessment of sexual side effects of LUTS/BPH treatments and efficacy of new therapeutic agents in LUTS/BPH and associated erectile dysfunction.

  • 出版日期2012-11